within Pharmacolibrary.Drugs.ATC.L;

model L01XJ03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.77,
    Cl             = 0.00027,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.376,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014166666666666666,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.224,
    k12             = 63.3,
    k21             = 63.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XJ03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Glasdegib is an oral small-molecule inhibitor of the hedgehog (Hh) signaling pathway, specifically targeting Smoothened (SMO). It is primarily used in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive chemotherapy. Glasdegib is FDA-approved.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with cancer (including AML), both male and female, after oral administration of glasdegib. Parameters represent a typical administration in clinical settings.</p><h4>References</h4><ol><li><p>Lam, JL, et al., &amp; Shaik, MN (2017). Metabolism, excretion and pharmacokinetics of [. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 47(12) 1064–1076. DOI:<a href=\"https://doi.org/10.1080/00498254.2016.1261307\">10.1080/00498254.2016.1261307</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27866461/\">https://pubmed.ncbi.nlm.nih.gov/27866461</a></p></li><li><p>Shaik, N, et al., &amp; LaBadie, RR (2019). Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 8(7) 895–902. DOI:<a href=\"https://doi.org/10.1002/cpdd.692\">10.1002/cpdd.692</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30977980/\">https://pubmed.ncbi.nlm.nih.gov/30977980</a></p></li><li><p>Masters, JC, et al., &amp; Shaik, N (2021). Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study. <i>Clinical pharmacology in drug development</i> 10(7) 707–717. DOI:<a href=\"https://doi.org/10.1002/cpdd.897\">10.1002/cpdd.897</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33356019/\">https://pubmed.ncbi.nlm.nih.gov/33356019</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XJ03;
